LENZ Therapeutics reports preliminary Q4 2025 results
LENZ Therapeutics, Inc., a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, has announced certain preliminary unaudited financial results for the fourth quarter ended December 31, 2025 and recent corporate updates. Approved by the FDA in August 2025, VIZZ is a once-daily aceclidine-based eye drop for the treatment of age-related presbyopia….

